---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-23-000062"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2023-10-12T23:59:59+00:00"
generated_at: "2026-06-10T00:43:13.096028+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Elicio Therapeutics terminates Chief Business Officer Annette Matthies without cause

## Summary
- Annette Matthies, Ph.D., Chief Business Officer, terminated without cause effective October 5, 2023.
- No replacement or interim successor named in the filing.
- Separation is effective as of the date of termination.

## SEC filing metadata
- accession: 0001601485-23-000062
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2023-10-12T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148523000062/0001601485-23-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148523000062/angn-20231005.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-23-000062
- JSON: https://secwatch.observer/filing/0001601485-23-000062.json
- Plain text: https://secwatch.observer/filing/0001601485-23-000062.txt

## Key facts
- Executive change
  Annette Matthies departed as Chief Business Officer at Elicio Therapeutics, Inc..
  - Action: terminated without cause
  - Role: Chief Business Officer
  source text: On October 5, 2023, Annette Matthies, Ph.D., Chief Business Officer of Elicio Therapeutics, Inc. (the “Company”) was terminated without cause, effective as of the same date (the “Separation Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601485/000160148523000062/0001601485-23-000062-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.